Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity.
4T1
CT26
CXCL9
CXCR3
DNA-encodable
IL-12
anti-PD-1
chemotaxis
electroporation
tavokinogene telseplasmid
Journal
Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776
Informations de publication
Date de publication:
16 Jun 2022
16 Jun 2022
Historique:
received:
05
10
2021
accepted:
15
04
2022
entrez:
20
5
2022
pubmed:
21
5
2022
medline:
21
5
2022
Statut:
epublish
Résumé
Clinical studies have demonstrated that local expression of the cytokine IL-12 drives interferon-gamma expression and recruits T cells to the tumor microenvironment, ultimately yielding durable systemic T cell responses. Interrogation of longitudinal biomarker data from our late-stage melanoma trials identified a significant on-treatment increase of intratumoral
Identifiants
pubmed: 35592387
doi: 10.1016/j.omto.2022.04.005
pii: S2372-7705(22)00057-2
pmc: PMC9092072
doi:
Types de publication
Journal Article
Langues
eng
Pagination
174-188Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
A.D. receives research support from Merck, BMS, Genentech, Pfizer, Incyte, Checkmate, and OncoSec; is an advisory board member of Novartis, Merck, Genentech, and Pfizer; and owns shares in Neugogen and Trex. A.A. receives research support and is an advisory board member, consultant, shareholder, and honorarium recipient with OncoSec; is an advisory board member and stock shareholder for Valitor Biosciences, an advisory board member and honorarium recipient for Regeneron and Array, and receives research support from Acerta, Amgen, AstraZeneca, BMS, Dynavax, Genentech, Idera, Incyte, ISA, LOXO, Merck, Novartis, Sensei, and Tessa. All other authors declare no competing interests.
Références
J Immunol. 2018 Jan 15;200(2):422-431
pubmed: 29311384
Front Immunol. 2018 Mar 01;9:414
pubmed: 29545811
Nat Immunol. 2015 Aug;16(8):850-8
pubmed: 26075911
Ann Oncol. 2020 Apr;31(4):532-540
pubmed: 32147213
Gene Ther. 2001 Feb;8(4):282-90
pubmed: 11313802
Cancer Microenviron. 2019 Dec;12(2-3):119-132
pubmed: 31583529
Front Med (Lausanne). 2018 Sep 25;5:271
pubmed: 30320116
Clin Cancer Res. 2017 Oct 1;23(19):5869-5880
pubmed: 28679778
Nat Med. 1996 Oct;2(10):1090-5
pubmed: 8837606
Res Immunol. 1993 Nov-Dec;144(9):695-8
pubmed: 8159870
Immunotherapy. 2017 Dec;9(16):1309-1321
pubmed: 29064334
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
J Biol Chem. 1995 Nov 10;270(45):27348-57
pubmed: 7592998
Cancer Immunol Res. 2020 Feb;8(2):246-254
pubmed: 31852717
Adv Exp Med Biol. 2017;1036:19-31
pubmed: 29275462
Cancer Res. 2009 Apr 1;69(7):3077-85
pubmed: 19293190
Cancer Res. 2004 Nov 1;64(21):7697-701
pubmed: 15520172
J Immunother. 2005 Jul-Aug;28(4):343-51
pubmed: 16000952
Cell Mol Immunol. 2017 Aug;14(8):662-674
pubmed: 28626234
Oncotarget. 2016 Apr 19;7(16):22174-85
pubmed: 26956047
EBioMedicine. 2019 Oct;48:169-177
pubmed: 31521609
Int J Cancer. 2002 May 1;99(1):149-53
pubmed: 11948506
Int Immunopharmacol. 2015 Oct;28(2):829-35
pubmed: 25907241
Front Oncol. 2019 Nov 15;9:1146
pubmed: 31799175
Cell Death Differ. 2015 Feb;22(2):237-46
pubmed: 25190142
Cancer Immunol Res. 2018 Sep;6(9):990-1000
pubmed: 30181337
Immunology. 2014 Sep;143(1):109-19
pubmed: 24679047
Oncoimmunology. 2013 Aug 1;2(8):e25752
pubmed: 24083082
Exp Cell Res. 2011 Mar 10;317(5):620-31
pubmed: 21376175
Int J Clin Exp Pathol. 2015 Nov 01;8(11):14725-32
pubmed: 26823797
Clin Cancer Res. 2020 Feb 1;26(3):598-607
pubmed: 31582519
Front Immunol. 2019 Oct 15;10:2453
pubmed: 31681327
Cancer Cell. 2019 Jun 10;35(6):885-900.e10
pubmed: 31185212
J Exp Med. 1995 Nov 1;182(5):1301-14
pubmed: 7595201
Clin Cancer Res. 2021 May 1;27(9):2481-2493
pubmed: 33593880
Immunity. 2019 Jun 18;50(6):1498-1512.e5
pubmed: 31097342
J Immunol. 2008 May 15;180(10):6713-24
pubmed: 18453591
Nature. 2019 Dec;576(7787):465-470
pubmed: 31827286
Cancer Res. 2006 Jun 1;66(11):5527-36
pubmed: 16740684
J Immunol. 2006 Feb 1;176(3):1456-64
pubmed: 16424173
Gene Ther. 2019 Feb;26(1-2):1-15
pubmed: 30323352
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Nat Commun. 2015 Jun 25;6:7458
pubmed: 26109379
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7240-E7249
pubmed: 27799536
Clin Cancer Res. 2020 Jan 15;26(2):487-504
pubmed: 31636098
Gene Ther. 2018 Apr;25(2):93-103
pubmed: 29523878
Cancer Immunol Immunother. 2012 Oct;61(10):1671-82
pubmed: 22382361
J Immunother. 2007 May-Jun;30(4):417-24
pubmed: 17457216
Trends Immunol. 2012 Oct;33(10):496-504
pubmed: 22726608
Nat Rev Immunol. 2017 Sep;17(9):559-572
pubmed: 28555670
Clin Cancer Res. 2020 Jun 15;26(12):2827-2837
pubmed: 32376655
Clin Cancer Res. 2016 Aug 15;22(16):4119-32
pubmed: 26964571
Cancer Metastasis Rev. 2019 Sep;38(3):417-430
pubmed: 31482487
Immunity. 2018 Dec 18;49(6):1148-1161.e7
pubmed: 30552023